High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey.

Abstract:

BACKGROUND:Southern African countries have borne the brunt of the HIV/AIDS pandemic. Monitoring epidemiological dynamics is critical to identify the populations at greatest risk of infection and to guide control strategies. METHODS:A cross-sectional community-based study to determine age- and sex-specific HIV prevalence among individuals aged 18-47 years was carried out in Manhiça, southern Mozambique. Participants were randomly selected from the demographic surveillance system in place in the area and voluntary HIV counselling and testing were offered at home. In addition, HIV prevalence estimates from the antenatal clinic (ANC) were collected prospectively. RESULTS:A total of 839 individuals were invited to participate in the study. Of these, 722 were recruited (50.7% women). The overall HIV prevalence in the community was 39.9% [95% confidence interval (CI) 35.9-43.8%]. By age, the prevalence was 23.2% (95% CI 17.9-28.6%) in individuals aged 18-27 years, 41.2% (95% CI 35.6-48.3%) in those aged 28-37 years and 44.8% (95% CI 38.4-51.2%) in those aged 38-47 years. HIV prevalence was higher among women than men in all age groups. The overall HIV prevalence estimate for women in the community (43.1%; 95% CI 37.6-48.5%) was 1.4 times higher than that for those attending the ANC (29.4%; 95% CI 26.7-32.0%). CONCLUSIONS:The high HIV prevalence found in this region suggests that the epidemic is in a mature stable phase. The lower rates in the ANC than in the community suggest that ANC evaluations may underestimate community HIV prevalence. Resources to monitor HIV infection dynamics are needed to guide targeted control strategies in countries in which the epidemic exacts the greatest toll.

journal_name

HIV Med

journal_title

HIV medicine

authors

González R,Munguambe K,Aponte J,Bavo C,Nhalungo D,Macete E,Alonso P,Menéndez C,Naniche D

doi

10.1111/j.1468-1293.2012.01018.x

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

581-8

issue

10

eissn

1464-2662

issn

1468-1293

journal_volume

13

pub_type

杂志文章
  • Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

    abstract:OBJECTIVES:Socio-economic factors and lifestyle are known to differ across geographies and populations, which may result in distinct risk profiles for cardiovascular disease (CVD). This study assessed carotid intima-media thickness (CIMT), a proxy for CVD, and its determinants in two groups of people living with HIV (P...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12831

    authors: Roozen G,Vos AG,Tempelman HA,Venter W,Grobbee DE,Scheuermaier K,Klipstein-Grobusch K

    更新日期:2020-07-01 00:00:00

  • Associations of marijuana with markers of chronic lung disease in people living with HIV.

    abstract:OBJECTIVES:The relationship between marijuana use and markers of chronic lung disease in people living with HIV (PLWH) is poorly understood. METHODS:We performed a cross-sectional analysis of the Examinations of HIV-Associated Lung Emphysema (EXHALE) study, including 162 HIV-positive patients and 138 participants with...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12966

    authors: Wenger DS,Triplette M,Shahrir S,Akgun KM,Wongtrakool C,Brown ST,Kim JW,Soo Hoo GW,Rodriguez-Barradas MC,Huang L,Feemster LC,Zifodya J,Crothers K

    更新日期:2021-02-01 00:00:00

  • Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

    abstract:BACKGROUND:Tuberculosis (TB) is a common opportunistic infection among HIV-infected people, and rifampicin is an important drug for the treatment of TB. However, administration of rifampicin in combination with antiretroviral therapy, particularly protease inhibitors, is difficult because of drug-drug interactions. ME...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00442.x

    authors: Mallolas J,Sarasa M,Nomdedeu M,Soriano A,López-Púa Y,Blanco JL,Martínez E,Gatell JM

    更新日期:2007-03-01 00:00:00

  • Hepatitis B virus surface antigen and anti-hepatitis C virus rapid tests underestimate hepatitis prevalence among HIV-infected patients.

    abstract:OBJECTIVES:In the case of coinfection with HIV and hepatitis B virus (HBV) and/or hepatitis C virus (HCV), hepatic disease progression is often accelerated, with higher rates of liver cirrhosis and liver-related mortality. We aimed to evaluate the performance of the rapid tests used routinely to detect HBV surface anti...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12158

    authors: Hønge B,Jespersen S,Medina C,Té D,da Silva Z,Ostergaard L,Laursen A,Wejse C,Krarup H,Erikstrup C,Bissau HIV cohort study group.

    更新日期:2014-10-01 00:00:00

  • Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

    abstract:OBJECTIVES:We evaluated the emergence of drug resistance in patients failing first-line regimens containing one nonnucleoside reverse transcriptase inhibitor (NNRTI) administered with zidovudine (ZDV) + lamivudine (the ZDV group) or non-thymidine analogues (non-TAs) (tenofovir or abacavir, + lamivudine or emtricitabine...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12044

    authors: Santoro MM,Sabin C,Forbici F,Bansi L,Dunn D,Fearnhill E,Boumis E,Nicastri E,Antinori A,Palamara G,Callegaro A,Francisci D,Zoncada A,Maggiolo F,Zazzi M,Perno CF,Ceccherini-Silberstein F,Mussini C

    更新日期:2013-10-01 00:00:00

  • Prevention of cryptococcosis in HIV-infected patients with limited access to highly active antiretroviral therapy: evidence for primary azole prophylaxis.

    abstract::Despite advances in the treatment of HIV disease, the incidence and mortality of invasive cryptococcal disease remain significant. A matched, case-control study was performed to examine the impact of highly active antiretroviral therapy (HAART) and azole use on the incidence of invasive cryptococcal disease in HIV-inf...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00289.x

    authors: Cantey PT,Stephens DS,Rimland D

    更新日期:2005-07-01 00:00:00

  • Psychological wellbeing and use of alcohol and recreational drugs: results of the British HIV Association (BHIVA) national audit 2017.

    abstract:OBJECTIVES:The aim of this national audit was to assess adherence of services providing HIV care in the UK to national standards and guidelines regarding psychological support and the assessment of alcohol and recreational drug use (including chemsex drugs) in people living with HIV (PLWH). METHODS:Participating sites...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12744

    authors: Parry S,Curtis H,Chadwick D,British HIV Association Audit and Standards Sub-Committee.

    更新日期:2019-07-01 00:00:00

  • The role of tenofovir alafenamide in future HIV management.

    abstract::HIV infection has become a chronic condition rather than an acute life-threatening disease in developed countries, thanks to consistent innovation and evolution of effective interventions. This has altered HIV management and created new challenges. People living with HIV (PLWHIV) are living longer and so encounter com...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1111/hiv.12401

    authors: Antela A,Aguiar C,Compston J,Hendry BM,Boffito M,Mallon P,Pourcher-Martinez V,Di Perri G

    更新日期:2016-05-01 00:00:00

  • Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.

    abstract:OBJECTIVE:Study 903 was a 144-week, randomized, double-blind, active-controlled study of tenofovir disoproxil fumarate (TDF) therapy in treatment-naive HIV-1-infected patients. Patients received either TDF (n = 299) or stavudine (d4T) (n = 301) with lamivudine (3TC) and efavirenz (EFV). Resistance analyses were perform...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2006.00404.x

    authors: Margot NA,Lu B,Cheng A,Miller MD,Study 903 Team.

    更新日期:2006-10-01 00:00:00

  • Role and interpretation of fluorodeoxyglucose-positron emission tomography/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study.

    abstract:OBJECTIVES:The aim of the study was to evaluate prospectively the usefulness of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in investigation of fever of unknown origin (FUO) in HIV-positive patients and to determine whether HIV viraemia impacts on FDG-PET/CT performance. METHODS:Th...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12030

    authors: Martin C,Castaigne C,Tondeur M,Flamen P,De Wit S

    更新日期:2013-09-01 00:00:00

  • Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

    abstract:OBJECTIVES:Abacavir (ABC) selects for four mutations (K65R, L74V, Y115F and M184V) in HIV-1 reverse transcriptase (RT), both in vitro and during monotherapy in vivo. The aim of this analysis was to compare the selection of these and other nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations by ABC-con...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00243.x

    authors: Lanier ER,Givens N,Stone C,Griffin P,Gibb D,Walker S,Tisdale M,Irlbeck D,Underwood M,St Clair M,Ait-Khaled M

    更新日期:2004-11-01 00:00:00

  • Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

    abstract:OBJECTIVES:The aim of the study was to compare the neuropsychiatric safety and tolerability of rilpivirine (TMC278) vs. efavirenz in a preplanned pooled analysis of data from the ECHO and THRIVE studies which compared the safety and efficacy of the two drugs in HIV-1 infected treatment naïve adults. METHODS:ECHO and T...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12012

    authors: Mills AM,Antinori A,Clotet B,Fourie J,Herrera G,Hicks C,Madruga JV,Vanveggel S,Stevens M,Boven K,ECHO and THRIVE study groups.

    更新日期:2013-08-01 00:00:00

  • Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.

    abstract:OBJECTIVES:Despite the huge success of antiretroviral therapy (ART), there is an ongoing HIV epidemic among men who have sex with men (MSM) in resource-rich countries. Understanding the driving factors underlying this process is important for curbing the epidemic. METHODS:We simulated the HIV epidemic in MSM in Switze...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12660

    authors: Kusejko K,Marzel A,Hampel B,Bachmann N,Nguyen H,Fehr J,Braun DL,Battegay M,Bernasconi E,Calmy A,Cavassini M,Hoffmann M,Böni J,Yerly S,Klimkait T,Perreau M,Rauch A,Günthard HF,Kouyos RD,Swiss HIV Cohort Study.

    更新日期:2018-11-01 00:00:00

  • Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

    abstract:BACKGROUND:The addition of a low dose of ritonavir to protease inhibitors (PIs) has become a widespread strategy to improve PI pharmacokinetics. As resistance is a major barrier to long-term suppression, in salvage therapy genotype and/or phenotype scoring is currently used to predict the response. We evaluated the rel...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00464.x

    authors: Mallolas J,Blanco J,Labarga P,Vergara A,Ocampo A,Sarasa M,Arnedo M,López-Púa Y,García J,Juega J,Guelar A,Terrón A,Dalmau D,García I,Zárraga M,Martínez E,Carné X,Pumarola T,Escayola R,Gatell J

    更新日期:2007-05-01 00:00:00

  • HIV prevalence and HIV clinical outcomes of transgender and gender-diverse people in England.

    abstract:OBJECTIVES:We provide the first estimate of HIV prevalence among trans and gender-diverse people living in England and compare outcomes of people living with HIV according to gender identity. METHODS:We analysed a comprehensive national HIV cohort and a nationally representative self-reported survey of people accessin...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12987

    authors: Kirwan PD,Hibbert M,Kall M,Nambiar K,Ross M,Croxford S,Nash S,Webb L,Wolton A,Delpech VC

    更新日期:2021-02-01 00:00:00

  • Knowledge of their children's HIV status in HIV-positive mothers attending a genitourinary medicine clinic in the UK.

    abstract:OBJECTIVES:To determine whether HIV-infected mothers knew the HIV status of their children, enabling the offer of targeted testing of children at risk. METHODS:All HIV-positive women attending the genitourinary medicine clinic at a district general hospital in the United Kingdom were asked whether they had children an...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2008.00556.x

    authors: Eisenhut M,Sharma V,Kawsar M,Balachandran T

    更新日期:2008-04-01 00:00:00

  • A global survey of HIV-positive people's attitudes towards cure research.

    abstract:OBJECTIVES:Involvement of people living with HIV (PLHIV) in the design of HIV cure studies is important, given the potential risks to participants. We present results of an international survey of PLHIV to define these issues and inform cure research. METHODS:PLHIV were recruited in June-November 2014 through HIV webs...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12391

    authors: Simmons R,Kall M,Collins S,Cairns G,Taylor S,Nelson M,Fidler S,Porter K,Fox J,Collaborative HIV Eradication of viral Reservoirs (CHERUB) Survey collaboration.

    更新日期:2017-02-01 00:00:00

  • Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

    abstract:OBJECTIVES:TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, protease inhibitor-naïve, HIV-1-infected patients. ...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2008.00644.x

    authors: Ruxrungtham K,Pedro RJ,Latiff GH,Conradie F,Domingo P,Lupo S,Pumpradit W,Vingerhoets JH,Peeters M,Peeters I,Kakuda TN,De Smedt G,Woodfall B,TMC125-C227 study group.

    更新日期:2008-11-01 00:00:00

  • Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

    abstract:OBJECTIVES:Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been associated with high interindividual variation in efavirenz pharmacokinetics. However, clinical data on the relationship of CYP2B6 polymorphisms with the occurrence of efavirenz-induced central nervous system (CNS) symptoms are l...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12488

    authors: Gallien S,Journot V,Loriot MA,Sauvageon H,Morlat P,Reynes J,Reliquet V,Chêne G,Molina JM,ANRS 099 ALIZE trial study group.

    更新日期:2017-09-01 00:00:00

  • Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy.

    abstract:OBJECTIVE:The aim of the study was to compare the incidence of anaemia in patients treated with zidovudine (ZDV) with that in patients treated with highly active antiretroviral therapy (HAART) not including ZDV. METHODS:Using HIV Insight, a database of abstracted US HIV care centre medical charts, ZDV-naïve patients s...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00500.x

    authors: Curkendall SM,Richardson JT,Emons MF,Fisher AE,Everhard F

    更新日期:2007-11-01 00:00:00

  • Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).

    abstract:BACKGROUND:More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005. DESIGN AND METHODS:In 2005, 34 departments prospectively recorded all dea...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00686.x

    authors: Rosenthal E,Salmon-Céron D,Lewden C,Bouteloup V,Pialoux G,Bonnet F,Karmochkine M,May T,François M,Burty C,Jougla E,Costagliola D,Morlat P,Chêne G,Cacoub P,Mortavic\/Mortalité 2005 Study Group.

    更新日期:2009-05-01 00:00:00

  • Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.

    abstract:OBJECTIVES:Certain non-AIDS-related diseases have been associated with immunodeficiency and HIV RNA levels in HIV-infected patients on combination antiretroviral therapy (cART). We aimed to investigate these associations in patients not yet on cART, when potential antiretroviral-drug-related effects are absent and vari...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12202

    authors: Zhang S,van Sighem A,Kesselring A,Gras L,Prins JM,Hassink E,Kauffmann R,Richter C,de Wolf F,Reiss P,ATHENA national observational HIV cohort study.

    更新日期:2015-05-01 00:00:00

  • Late presentation of HIV infection: a consensus definition.

    abstract:OBJECTIVES:Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course of their infection. Surveillance to identify the extent to which late presentation occurs remains inadequate across Europe and is further complicated by the lack of a common clinical definition of...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00857.x

    authors: Antinori A,Coenen T,Costagiola D,Dedes N,Ellefson M,Gatell J,Girardi E,Johnson M,Kirk O,Lundgren J,Mocroft A,D'Arminio Monforte A,Phillips A,Raben D,Rockstroh JK,Sabin C,Sönnerborg A,De Wolf F,European Late Presenter

    更新日期:2011-01-01 00:00:00

  • Monitoring HIV-indicator condition guided HIV testing in Estonia.

    abstract:OBJECTIVES:The aim of the study was to assess indicator condition (IC) guided HIV testing in Estonia from 2012-2015. METHODS:We used Estonian Health Insurance Fund (EHIF) data. EHIF is the core purchaser of health care services in Estonia, covering health care costs for insured people (94% of the total population). Af...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12586

    authors: Rüütel K,Lemsalu L,Lätt S,OptTEST by HiE.

    更新日期:2018-02-01 00:00:00

  • A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.

    abstract:OBJECTIVES:Low-dose stavudine therapy may have a lower toxicity profile compared with standard dose. A randomized controlled trial comparing these two doses of stavudine with tenofovir disoproxil fumarate (tenofovir DF) was performed to assess the effects on anthropometry, markers of inflammation, and lipid and glucose...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12074

    authors: Menezes CN,Crowther NJ,Duarte R,Van Amsterdam D,Evans D,Dickens C,Dix-Peek T,Rassool M,Prinsloo A,Raal F,Sanne I

    更新日期:2014-01-01 00:00:00

  • Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

    abstract:BACKGROUND:The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy wit...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2009.00752.x

    authors: Ghosn J,Flandre P,Cohen-Codar I,Girard PM,Chaix ML,Raffi F,Dellamonica P,Ngovan P,Norton M,Delfraissy JF,MONARK Study Group.

    更新日期:2010-02-01 00:00:00

  • How reliable is an undetectable viral load?

    abstract:OBJECTIVES:An article by the Swiss AIDS Commission states that patients with stably suppressed viraemia [i.e. several successive HIV-1 RNA plasma concentrations (viral loads, VL) below the limits of detection during 6 months or more of highly active antiretroviral therapy (HAART)] are unlikely to be infectious. Questio...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00714.x

    authors: Combescure C,Vallier N,Ledergerber B,Cavassini M,Furrer H,Rauch A,Battegay M,Bernasconi E,Vernazza P,Hirschel B,Swiss HIV Cohort Study.

    更新日期:2009-09-01 00:00:00

  • Regulation of adiponectin in adipocytes upon exposure to HIV-1.

    abstract:OBJECTIVES:Adipose dysregulation, dyslipidemia, and insulin resistance are hallmarks of HIV-related lipodystrophy. The precise mechanisms behind these disturbances are unknown. In HIV-infected patients, we previously demonstrated a strong relationship between lipodystrophy and levels of adiponectin, an adipose peptide ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2006.00372.x

    authors: Sankalé JL,Tong Q,Hadigan CM,Tan G,Grinspoon SK,Kanki PJ,Hotamisligil GS

    更新日期:2006-05-01 00:00:00

  • Euthanasia: from the perspective of HIV infected persons in Europe.

    abstract:BACKGROUND:In the debate about legalization of euthanasia very little attention has so far been given to the opinion of the patient. OBJECTIVE:To assess the opinion of persons with HIV infection in Europe. METHODS:A cross-sectional survey of persons with HIV infection attending HIV/AIDS treatment centres or HIV suppo...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2001.00053.x

    authors: Andraghetti R,Foran S,Colebunders R,Tomlinson D,Vyras P,Borleffs CJ,Fleerackers Y,Schrooten W,Borchert M

    更新日期:2001-01-01 00:00:00

  • Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort.

    abstract:BACKGROUND:GB virus type C (GBV-C) viraemia is associated with a beneficial outcome in HIV-infected individuals in several though not all studies. GBV-C viraemia was examined in a matched case-control study of 133 HIV-infected pregnant women who transmitted HIV to their infants ('cases') and 266 non-transmitting contro...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00510.x

    authors: Handelsman E,Cheng I,Thompson B,Hershow R,Mofenson LM,Hollinger FB,Chen KT,Burchett SK,Klinzman D,Stapleton JT,Women and Infants Transmission Study Group (WITS).

    更新日期:2007-11-01 00:00:00